Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-281 (ocrelizumab biosimilar) in relapsing-remitting multiple sclerosis
NCT07321093Phase 3Recruiting
- Sponsor
- BIOCAD
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by BIOCAD. Started Nov 2025; status: recruiting.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT07321093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321093.